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through error-prone repair appears to be
restricted to a subset of sites upon which
AID acts (Liu et al., 2008). Thus mutation
is not an obligate consequence of AID
activity. TheAidca155/mouse further sug-
gests that in some settings AID might pro-
mote genomic instability in the absence of
obvious mutagenesis.
The demonstration that miR-155 re-
presses the expression of AID—or indeed
that any miRNA represses any other tran-
script—provokes consideration of how
the processing of pri- and pre-miRNAs is
regulated and how transcription of pri-
miRNAs is controlled. Engagement of sur-
face Ig induces Bic transcripts in B cells,
but accumulation of miR-155 is not nec-
essarily correlated with accumulation of
its pri-miRNA (Kluiver et al., 2007). Clearly,
we have much to learn before we can un-
derstand how the abundance of miR-155
is governed. Until then, we are left with
the question posed by the Roman satirist
Juvenal: ‘‘Quis custodiet ipsos custo-
des?’’—‘‘Who watches the watchers?’’
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The molecular mechanisms that underlie T cell anergy remain unclear. In this issue of Immunity, Teague et al.
(2008) report that anergy may occur at the level of T cell receptor complex.Immune tolerance of T cells to self-
antigen is achieved through multiple
mechanisms (Schwartz, 2003). In addition
to the existence of negative selection
in the thymus, autoreactive T cells that
evade thymic deletion are functionally
silent in the periphery via anergy or
extracellular suppression by environment
factors such as regulatory T cells. T cell
anergy represents a state of cells that
cannot give rise to a productive response
upon stimulation with antigen. Although
anergic cells exhibit a systemic impair-
ment in multiple T cell receptor (TCR)
downstream signaling pathways, the pre-
cise defect in the TCR signaling cascade
and molecular mechanisms leading to
such a defect remain unclear.
In this issue of Immunity, Teague et al.
(2008) have provided new insights into598 Immunity 28, May 2008 ª2008 Elsevier Ithis enigma. These authors previously
established amousemode for T cell toler-
ance in which T cells expressed a trans-
genic (Tg) Va3Vb12 TCR specific for
friend murine leukemia virus (FMuLV)
Gag protein that was specifically ex-
pressed in the liver cells (Ohlen et al.,
2002). Peripheral CD8+ (TCRGag) T cells
in these mice were anergic because they
exhibited weak TCR signaling and were
unable to proliferate in response to stimu-
lation with autoantigen Gag peptide. In-
terestingly, in the current study, Teague
et al. (2008) find that although naive
TCRGag CD8+ T cells respond vigorously
to both Gag-peptide and anti-CD3 stimu-
lation, tolerant CD8+ T cells, which failed
to respond to the stimulation of Gag pep-
tide, unexpectedly proliferate after anti-
CD3 triggering. Antibodies specificallync.against the transgenic Va3Vb12 chains,
which induced proliferation of naive
TCRGag T cells, could not induce the toler-
ant T cells to proliferate. This observation
thus suggests that the proliferation might
reflect the response of tolerant TCRGag T
cells induced via a second, endogenously
rearranged TCR. Alternatively, it may also
suggest that the proliferation was contrib-
uted by nontolerant T cells expressing
only an endogenous TCR or that TCR sig-
nals generated by anti-CD3 stimulation
are stronger than those induced by the
antibody against the tolerant TCRab
chains. To discriminate these possibili-
ties, Teague et al. (2008) crossed TCRGag
mice to Rag-deficient mice so that rear-
rangement of the endogenous TCR was
prevented. They find that the resulting
tolerant Rag1/ TCRGag T cells are no
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PreviewsFigure 1. A Model of Immune-Tolerant versus -Competent TCR Complexes
Immune-competent TCR is associated with the CD3 complex containing CD3z, CD33, CD3g, and CD3d
chains. Interaction of the TCR with a tolerogen results in ubiquitination of CD3 such as the CD3z chain
and internalization and segregation of the TCR from CD3 components. Although the dissociated CD3
components are sorted to lysosome for degradation, the remaining incomplete TCR-CD3 complex may
be recycled back to the cell surface. The incomplete TCR-CD3 complex lacks CD3z andCD33 chains nec-
essary for transducing the productive TCR signals and thus are functionally anergized. Because anergized
T cells have normal intracellular signaling machinery, they can be fully activated by nontolerized TCR
expressed by the same cells.longer responsive to anti-CD3, thus ex-
cluding the possibility that the prolifera-
tion was caused by CD3 associated with
the tolerized TCRab. To directly assess
whether a nontolerant TCR expressed by
anergic T cells may deliver the productive
signals, the authors generated dual-TCR-
expressing T cells by crossing TCRGag Tg
mice to P14 TCR Tg mice, which express
the Va2Vb8 TCR specific for the Db-
restricted Gp33 epitope of lymphocytic
choriomeningits virus (LCMV) antigen.
The dual-TCR T cells isolated from the
liver-specific Gag Tg mice could not
respond to Gag peptide or to anti-TCR
Va3Vb12 stimulation, indicating that
these cells were anergic to autoantigen
Gag. Interestingly, the same anergic
T cells proliferate in response to Gp33-
peptide or anti-Va2Vb8 stimulation as effi-
ciently as that of naive TCRGag P14 dual-
TCR-expressing T cells. These data thus
provide firm evidence that anergic T cells
generated in this animal model are intrin-
sically immune competent and that the
anergy is likely established at the level of
the self-reactive TCR complex rather
than at the distal end of the TCR signaling
cascade. This phenomenon was not
unique to Gag-reactive TCR because inanother experimental setting in which
T cell anergy to the LCMV was induced
by repeated injection of high doses of
Gp33 peptide in incomplete Freund’s
adjuvant, T cell proliferation could be in-
duced through the nontolerant TCRGag
by Gag but not Gp33 peptide.
An important question raised by the
above data is what the molecular nature
of tolerized TCR versus immune compe-
tent TCR is. It was believed that the
anergic state of T cells is maintained at
the level of TCR-proximal signaling cas-
cade, because stimulation of anergic cells
through the TCR cannot activate the distal
signaling events such as activation of
MAP kinases and Ca2+ mobilization (Ap-
pleman and Boussiotis, 2003; Li et al.,
1996). Consistently, it has been reported
that stimulation with PMA and inomycin,
which bypasses TCR proximal signaling,
may elicit the response of anergic T cells
(Schwartz, 2003). Here, in line with the
above observations, Teague et al. (2008)
reported that in tolerant dual-TCR T cells,
the tolerant TCRGag could not as effi-
ciently activate the kinases Erk and JNK
as did the immune-competent P14 TCR.
The tolerant TCR also failed to aggregate
lipid rafts to form immunological synapseImmupon crosslinking with Gag peptide. Most
strikingly, immunoprecipitation of TCRGag
from tolerant dual-TCR T cells could not
bring down CD33 and CD3z chains, as did
the P14 TCR. This finding thus allowed
the authors to propose that the composi-
tion of anergic TCRcomplex is qualitatively
different from that of immune-competent
TCR (Figure 1). Another question that was
not answered is how anergic dual TCR T
cells can maintain the disparity of CD3
components in tolerized and immune-
competent TCR complexes. It has been
observed that the TCR is constitutively in-
ternalized in T cells no matter whether or
not Tcells are triggeredbyantigens. Incon-
trast to a nonstimulated TCR, which is
usually recycled back to the cell surface
after the internalization, ligand-triggered
TCR complex is sorted to lysosome for
degradation, a process that depends on
the Cbl family of ubiquitin ligases (Nara-
mura et al., 2002). Interestingly, it has
been reported that ablation of Cbl proteins
attenuates CD3z chain ubiquitination and
degradation, and T cells deficient in Cbl-b
cannot be anergized in vivo (Bachmaier
et al., 2000; Chiang et al., 2000). Thus, it
is envisioned that generation of tolerized
TCR in anergic T cells might involve the
process of ubiquitination mediated by
Cbl-b (Figure 1).
The observation that anergic dual-TCR
T cells can be activated via nontolerized
TCR potentially has an important benefit
clinically. Because T cells recognizing tu-
mor cells are often anergic in vivo, expres-
sion of a nontolerant TCR on these cells
canbeusedasa tool toactivate thesecells
in tumor therapy. To test this possibility,
Teague et al. (2008) transferred naive or
anergic TCRGag P14 dual-TCR T cells into
wild-type or liver-specific Gag Tg mice.
The recipients were infected with LCMV
and then challenged with Gag+ FBL tumor
cells. They found that both naive and toler-
ant T cells had similar expansion 1 week
after the LCMV infection, and all recipients
survived the tumor challenge. In contrast,
the control mice that received either no T
cells or T cells but not infected by LCMV
developed fatal tumors. This result thus
supports the hypothesis that anergic tu-
mor-specific T cells can be activated by a
nontolerant TCR expressed by the same
cells. It also provides a new avenue of elic-
iting antitumor immunity in tumor therapy.
In contrast to the Burnet postulation
that each T cell expresses only one pairunity 28, May 2008 ª2008 Elsevier Inc. 599
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Previewsof TCRab chains, in both mice and
humans, approximately one-third of pe-
ripheral T cells are dual-TCR T cells, al-
though the number of cells with the cell
surface expression is low (Padovan
et al., 1993). If these dual-TCR T cells con-
tain anergic T cells against the self-anti-
gens, then activation of these cells via
the second TCR by environmental anti-
gens such as viruses may cause autoim-
mune diseases. However, it is intriguing
to notice that in the tolerant TCRGag P14
double TCR Tg mice, the LCMV infection
failed to induce any detectable autoim-
mune damage in the liver, which ex-
pressed Gag antigen. Thus, in the future,
understanding of the mechanisms thatType 1 Interferons
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Although interferon-b is the most po
enigmatic. In this issue of Immunity,
of type 1 interferons in taming brain
Type 1 interferons (IFNs) are a family of
cytokines consisting of IFN-b andmultiple
subtypes of IFN-a. Originally, these cyto-
kines were identified by their antiviral
properties, but now they are known to
possess anti-inflammatory effects. Type
1 interferons inhibit several components
of the immune system, and currently,
IFN-b is the clinician’s most popular
choice for initial treatment of relapsing re-
mitting multiple sclerosis (MS). In general,
IFN-b reduces relapses by approximately
one-third of the cases and somewhat
delays progression of disease. However,
it works in only 50% of patients with
MS, and its toxicities are frequent (Arna-
son, 1999). Despite its wide use, the
precise mechanism by which IFN-b -
suppresses CNS autoimmunity in MS is
still unclear. In a series of elegant experi-
ments described in this issue, Prinz et al.
600 Immunity 28, May 2008 ª2008 Elsevier Icaused such a discrepancy may help to
stimulate wanted immune response and
prevent unwanted autoimmune conse-
quences in clinical therapy.
REFERENCES
Appleman, L.J., and Boussiotis, V.A. (2003). Immu-
nol. Rev. 192, 161–180.
Bachmaier, K., Krawczyk, C., Kozieradzki, I., Kong,
Y.Y., Sasaki, T., Oliveira-dos-Santos, A., Mariatha-
san, S., Bouchard, D., Wakeham, A., Itie, A., et al.
(2000). Nature 403, 211–216.
Chiang, Y.J., Kole, H.K., Brown, K., Naramura, M.,
Fukuhara, S., Hu, R.J., Jang, I.K., Gutkind, J.S.,




pular treatment for multiple sclerois
Prinz et al. (2008) elucidate an intrigui
inflammation.
(2008) demonstrated that local produc-
tion of IFN-b in the central nervous sys-
tem (CNS) suppresses experimental
autoimmune encephalomyelitis (EAE) by
inhibiting expression of certain chemo-
kines and bymodulating antigen process-
ing and presentation in microglia and
macrophages.
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ing disease and with others participating
in the progression of paralysis. Obtaining
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, its mechanism of action remains
ng portrait of the pleiotropic effects
a considerable signature of interferon-
inducible proteins (Han et al., 2008). Cell
types targeted by IFN-b include, but are
not limited, to dendritic cells (DCs), T
cells, B cells, macrophages, neutrophils,
microglia, astrocytes, and neurons. Sec-
ond, the effects of IFN-b are not limited
to only one of these specific cell types.
Type 1 IFN receptors (IFNARs) are ex-
pressed on a wide variety of cells and tis-
sues. Furthermore, IFN-b has been shown
to inhibit several inflammatory processes
of the immune system, including downre-
gulation of the expression of MHC class II
molecules on DCs, suppression of pro-
inflammatory cytokine production, reduc-
tion of proliferation of T cells, limitation
of immune cell trafficking, and promotion
of the integrity of endothelial cell barrier
between the blood and the CNS (Benve-
niste and Qin, 2007).
